JNJ PR read to me like trial reached pre-specified co-primary endpoint of MACE, stopping early mainly referred to planned trial finish timeline. How timeline was determined wasn't clear. Since no mention of the other co-primary endpoint of bleeding, my guess is it wasn't reached, but DSMB decided to stop for MACE co-primary endpoint. So this analysis was planned.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.